Corcept Therapeutics Inc.'s
) key objective in 2014 is the successful commercialization of
its only approved product, Korlym.
Corcept launched Korlym in the U.S in Apr 2012. Korlym is
approved in the U.S. and the EU as a once-daily oral medication
for the treatment of hyperglycemia secondary to hypercortisolism
in adults suffering from endogenous Cushing's syndrome, who have
type II diabetes or glucose intolerance.
We remind investors that Corcept enjoys orphan drug
designation for Korlym from the U.S. Food and Drug Administration
(FDA) for the approved indication.
Corcept recently announced plans to extend its development
program for glucocorticoid receptor (GR) antagonists, including
Korlym, into oncology. The company plans to expand its
development program based on encouraging early clinical and
pre-clinical data from leading academic institutions including
the University of Chicago.
The data shows the efficacy of cortisol, a glucocorticoid
stress hormone, and its receptors in chemotherapy resistance,
particularly for women suffering from relapsed, metastatic
triple-negative breast cancer (TNBC), a form of the disease with
a poor prognosis.
We note that Corcept has licensed patent rights from the
University of Chicago's Center for Technology Development &
Ventures, for the use of GR antagonists in combination with
chemotherapy in the treatment of estrogen-receptor-negative
breast cancer, a form of cancer that includes TNBC.
Based on positive data from the studies conducted by the
University of Chicago, Corcept has filed an investigational new
drug (IND) application with the FDA. Corcept also plans to
conduct its own multi-center, phase I clinical study of Korlym in
Eisai Co., Ltd.'s
We are encouraged by the company's efforts to commercialize
Korlym and develop it for additional indications.
Corcept currently carries a Zacks Rank #3 (Hold). Right now,
) look attractive. Both carry a Zacks Rank #1 (Strong Buy).
CORCEPT THERAPT (CORT): Free Stock Analysis
EISAI CO LTD (ESALY): Get Free Report
FOREST LABS A (FRX): Free Stock Analysis
SHIRE PLC-ADR (SHPG): Free Stock Analysis
To read this article on Zacks.com click here.